VKTXViking Therapeutics, Inc.
$28.50+12% 1Y
$28.50
$24.9752 weeks$40.87
VKTX as reported
Viking Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 5 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied
- Net income
- −$535M
Net income · +212% year on year · trailing twelve months to Q2 2026
- EPS
- −$4.67
EPS · +205% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q2 2026 |
| Net income | −$535M | +212% | Q2 2026 |
| EPS | −$4.67 | +205% | Q2 2026 |
| ROE | −79% | n/a | Q2 2026 |
| ROA | −66% | n/a | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Viking Therapeutics, Inc. (VKTX) · Revenue and profitRevenue and profitViking Therapeutics, Inc. (VKTX)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
On our screens:Most shorted stocks